A COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the companies announced on Monday.
Sanofi, GlaxoSmithKline set to start Phase 3 trials for COVID-19 vaccine after earlier setback
Post a Comment